Torsades de pointes related with the use of rupatadine;Torsade de pointes relacionadas con el uso de rupatadina

Revista Espanola de Cardiologia

Volumn 62, Issue 3, 2009, Pages 330-331

  Fité Mora, Ramon ^a  

^a Grupo Uriach   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN; RUPATADINE; SERTRALINE; TERFENADINE;

ADVERSE OUTCOME; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG INHIBITION; DRUG SAFETY; HEART ELECTROPHYSIOLOGY; HUMAN; LETTER; QT INTERVAL; SEX DIFFERENCE; TORSADE DES POINTES;

EID: 63849319209     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/S0300-8932(09)70382-3     Document Type: Editorial

References (7)

1. L. Nombela-Franco, B. Ruiz-Antorán, J. Toquero-Ramos, and L. Silva-Melchor Torsades de pointes relacionadas con el uso de rupatadina Rev Esp Cardiol 61 2008 328 329
2. 8th Periodic Safety Update Report. Rupatadine. J. Uriach & Cía. 1 July 2006 - 30 June 2007.
3. E. Donado, O. García, and I. Pérez Cardiac safety of rupatadine according to the new ICH guideline: a "through QT/QTc study" [libro de resúmenes] XXV Congress of the European Academy of Allergology and Clinical Immunology 2006 Viena 216
4. American Society of Health System Pharmacists. AHFS Drug information 2006.
5. M.D. Johnson, G. Newkirk, and J.R. White Clinically significant interactions Postgrad Med 105 1999 193 222
6. Rupatadine (INN) Fumarate. Clinical Investigator's Brochure. J. Uriach y Compañía S.A.; 2005.
7. M. Amin, H. Lehmann, and J. Mirmiran A double-blind, placebo-controlled dose finding study with sertraline Psychopharmacol Bull 25 1989 164 167